A higher bar for investment is a credit to biotech, says Maraganore

“The bar has gotten higher because science has gotten so much better,” John Maraganore said on The BioCentury Show. Reflecting on the capital markets and the state of innovation, the founder and former CEO of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) painted a picture of a robust ecosystem fueled by sprawling innovation, where the higher scrutiny by investors will serve the industry well.

In a broad-ranging conversation, Maraganore gave his views on the innovation and funding landscape, geopolitical issues facing the industry and the outlook for the next generation of leaders. Since leaving Alnylam at the end of 2021, Maraganore has joined Arch Ventures, several biotech boards, and taken an active role in mentoring programs and non-profit foundations. He is also on the board of BIO, where he was chair in 2017-19. ...